Anticancer potential of Bacillus coagulans MZY531 on mouse H22 hepatocellular carcinoma cells via anti-proliferation and apoptosis induction
Authors:
Open Access
- 13 September 2023
- journal article
- research article
- Published by Springer Nature in BMC Complementary Medicine and Therapies
- Vol. 23 (1) , 1-9
Abstract
Bacillus coagulans have recently revealed its anticancer effects, but few investigations are available on their effects on liver cancer proliferation, and the precise mechanism to mark its impact on apoptosis-related signaling pathways has yet to be elucidated. The aim of this study was to evaluate the anti-proliferative effect of B. coagulans MZY531 and apoptosis induction in the mouse H22 hepatocellular carcinoma cell line. The anti-proliferative activity of B. coagulans MZY531 was evaluated by Cell Counting Kit-8 (CCK-8) assay, and cell apoptosis was revealed with Terminal Deoxynucleotidyl Transferase (TDT)-mediated dUTP Nick-End Labeling (TUNEL) staining and flow cytometric analysis. The expressions of apoptosis-related protein were determined by western blot analysis. The CCK-8 assay revealed that B. coagulans MZY531 inhibited the H22 cells proliferation in a concentration-dependent manner. TUNEL staining revealed an increased apoptosis rate in H22 cells following intervention with B. coagulans MZY531. Furthermore, flow cytometric analysis showed that B. coagulans MZY531 treatment (MOI = 50 and 100) significantly alleviated the H22 cells apoptosis compared with the control group. Western blot analysis found B. coagulans MZY531 significantly decreased level of phospho-PI3K (p-PI3K), phospho-AKT (p-AKT), and phospho-mTOR (p-mTOR) compared with the control group. Furthermore, H22 cells treatment with B. coagulans MZY531 enhanced the expression of caspase-3 and Bax and jeopardized the expression of Bcl-2. Taken together, apoptosis induction and cell proliferation inhibition via PI3K/AKT/mTOR and Bax/Bcl-2/Caspase-3 pathway are promising evidence to support B. coagulans MZY531 as a potential therapeutic agent for cancer.Keywords
This publication has 38 references indexed in Scilit:
- Programmed probiotics light up liver cancer in urineNature Reviews Gastroenterology & Hepatology, 2015
- Inhibition of Growth and Metastasis of Breast Cancer in Mice by Milk Fermented With Lactobacillus casei CRL 431Journal of Immunotherapy, 2015
- Well-balanced commensal microbiota contributes to anti-cancer response in a lung cancer mouse modelGenetics and Molecular Research, 2015
- The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probioticNature Reviews Gastroenterology & Hepatology, 2014
- The administration of milk fermented by the probiotic Lactobacillus casei CRL 431 exerts an immunomodulatory effect against a breast tumour in a mouse modelImmunobiology, 2014
- Rapid Induction of Apoptosis by PI3K Inhibitors Is Dependent upon Their Transient Inhibition of RAS–ERK SignalingCancer Discovery, 2014
- Targeting Apoptosis Pathways for New Cancer TherapeuticsAnnual Review of Medicine, 2014
- Novel Expression Patterns of PI3K/Akt/mTOR Signaling Pathway Components in Colorectal CancerJournal of the American College of Surgeons, 2010
- Differential induction of apoptosis in human colonic carcinoma cells (Caco-2) by Atopobium, and commensal, probiotic and enteropathogenic bacteria: Mediation by the mitochondrial pathwayInternational Journal of Food Microbiology, 2010
- Soluble Proteins Produced by Probiotic Bacteria Regulate Intestinal Epithelial Cell Survival and GrowthGastroenterology, 2007